Opportunities and Challenges in Biosimilars Development
Biological drugs constitute one of the largest growing sectors of the pharmaceutical industry, with total global sales in 2010 exceeding $110 billion. With patents for the top-selling biologics either already expired or due to expire within the next decade, there is a growing interest in developing biosimilars. Read more.
Optimizing Early Clinical Research to Accelerate Drug Development Timelines: Adaptive Study Design
Clinical Development is evolving. In the traditional paradigm, clients took a phased approach to drug development, starting with a scarce number of molecules and testing each one thoroughly, by progressing through pre-clinical testing, Phase I, II, and III studies. Read more.
Pulmonary Assessments in Early Clinical Research
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis continue to be an unmet medical need despite advances in clinical and scientific understanding of these diseases. Read more.
Overview: The Biosimilars Alliance
Driven by client demand for an integrated service solution for the development of biosimilar products, Celerion partnered with Ricerca Biosciences to form “The Biosimilars Alliance”, which is focused on preclinical and early clinical assessment of biologics manufactured by a new supplier. Read more.
Fiona McNeilly, MBA – Site Director, Belfast
Fiona is the Site Director at Celerion’s clinic in Belfast and is responsible for the overall execution and management of all clinical studies at the site. In her role, she has contributed to the growth and expansion of the services; including more complex studies for a variety of therapeutic areas. Read more.
Global Clinical Research: Belfast, Northern Ireland, UK
Celerion’s Global Clinical Research facility in Belfast offers clients experience and expertise from recruitment through to final report; best-in-class recruitment rate for studies that start on-time, extensive accreditation in exploratory Phase 0, I and lla clinical proof-of-concept studies involving patient and special populations. Read more.